Clinical trials: Prostate Cancer With Intermediate Risk, open to volunteers
Prostate Cancer (Adenocarcinoma), Low and Intermediate Risk Prostate Cancer
Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness
This clinical research study is intended to show that Micro-Ultrasound Guided Focal Laser Ablation (MicroUSgFLA) is a safe procedure that can significantly postpone or eliminate the need for patients with intermediate-Risk…
- Trial name
- MicroUSgFLA (NCT07339943)
- Testing
- 6 month, prospective, interventional single-arm safety and effectiveness study, The TRANBERG|CLS Thermal therapy
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer, Low and Intermediate Risk Prostate Cancer
MRI Guided Focal Laser Ablation of Prostate Cancer
This clinical research study is designed to determine the ability of in bore MRI guided Focal Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate.
- Trial name
- MRgFLA (NCT03650595)
- Testing
- The TRANBERGCLS|Thermal Therapy
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- University Health Network, Toronto
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment.
- Conditions
- Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
- Trial name
- ARPEGGIO (NCT07393867)
- Testing
- PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Martin T. King, MD, PhD
Prostate Cancer Patients Undergoing External Radiation and Seed Implantation, High Risk Localised Prostate Carcinoma
Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions
Every year, about 700 Danish men get radiotherapy for prostate cancer with a high-risk of later progression. The risk of relapse is about 40 % after 5 - 8 years, so we need better treatment for these patients in Denmark and…
- Conditions
- Prostate Cancer Patients Undergoing External Radiation and Seed Implantation, High Risk Localised Prostate Carcinoma, Locally Advanced Prostate Cancer, Unfavourable Intermediate Risk Prostate Cancer
- Trial name
- DAPROCA10 (NCT07343349)
- Testing
- Addition of focal boost and hypofractionation
- Where
- 3 sites in Denmark
- Volunteers
- 1,016 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Localized Prostate Cancer, Low Risk Prostate Cancer
The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
The investigators want to investigate whether it is possible to reduce the number of curative radiotherapy doses from 5 to only 3 for men with localized early prostate cancer.
- Conditions
- Localized Prostate Cancer, Low Risk Prostate Cancer, Intermediate Risk Prostate Cancer
- Trial name
- PRECISION (NCT06117059)
- Testing
- 3 fractions of prostate SBRT
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- NHS Lothian
Low-to-intermediate-risk Prostate Carcinoma
Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L)
A single institution with a single group, a phase II study, low- and medium-risk studies performed after biodegradable substance injection prostate cancer dosage increase.
- Trial name
- DESAR-L (NCT06461819)
- Testing
- Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center